ArticleCureus2025
Prevalence and Clinical Correlation of Intron 22 Inversion in Hemophilia A in Northeast India.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHemophilia A is an X-linked bleeding disorder caused by mutations in the F8 gene, with intron 22 inversion being the most common genetic alteration in severe cases. This study aimed to determine the prevalence of intron 22 inversion in hemophilia A patients in Assam, Northeast India, and evaluate its correlation with disease severity.
methodsThis hospital-based observational study included 80 hemophilia A patients at Assam Medical College from March 2023 to February 2024. Clinical history, coagulation tests (activated partial thromboplastin time (APTT), prothrombin time (PT), and factor VIII assay), and nested long-distance polymerase chain reaction (NLD-PCR) for intron 22 inversion detection were performed. Statistical analysis was conducted using SPSS v25 (IBM Corp., Armonk, New York, USA).
resultsAmong the 80 patients, 41 (51.25%) had severe hemophilia A, 22 (27.5%) moderate, and 17 (21.25%) mild. Intron 22 inversion was detected in 24 patients (30%), with a significantly higher prevalence in severe cases 22/41 (53.65%) compared to moderate 2/22 (9.09%) and mild cases (0%) (p < 0.001). APTT was significantly prolonged in severe cases (109.35 ± 15.62 sec) compared to moderate (86.92 ± 9.87 sec) and mild cases (61.71 ± 8.94 sec) (p < 0.001), reinforcing the genetic basis of disease severity.
conclusionThis study confirms a strong correlation between intron 22 inversion and severe hemophilia A, consistent with global and Indian studies. It emphasizes the need for routine genetic screening for early diagnosis and personalized treatment strategies, including genetic counseling. Future research should explore other F8 mutations, gene therapy, and the role of intron 22 inversion in inhibitor development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.